Status:

NOT_YET_RECRUITING

Enhancing Heart Allograft Function With the OCS Heart System Trial

Lead Sponsor:

TransMedics

Conditions:

Heart Transplant

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In additi...

Eligibility Criteria

Inclusion

  • Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):
  • Donor Inclusion Criteria
  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \<50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.
  • DBD donor hearts with an expected cross clamp of ≥ 4 hours
  • DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:
  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%
  • Donor Exclusion • Moderate to severe aortic incompetence
  • Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):
  • Donor Inclusion Criteria
  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • Eligible for randomization to OCS or SCS treatment arms.
  • DBD donor hearts with an expected cross clamp time of \< 4 hours.
  • Donor Exclusion
  • Moderate to severe aortic incompetence
  • DBD donor with any of the following organ quality concerns:
  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%
  • Recipient Eligibility Criteria (for Part A and B Cohorts)
  • Inclusion
  • Signed informed consent document and authorization to use and disclose protected health information
  • Heart transplant candidate
  • Age ≥ 18 years old
  • Exclusion
  • • Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Exclusion

    Key Trial Info

    Start Date :

    February 1 2026

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 30 2027

    Estimated Enrollment :

    655 Patients enrolled

    Trial Details

    Trial ID

    NCT07145515

    Start Date

    February 1 2026

    End Date

    July 30 2027

    Last Update

    November 25 2025

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Mount Sinai

    New York, New York, United States, 10029

    2

    Columbia University Irving Medical Center/ New York Presbyterian Hospital

    New York, New York, United States, 10032

    3

    Westchester Medical Center

    Valhalla, New York, United States, 10595

    4

    Duke University

    Durham, North Carolina, United States, 27710